Skip to content

Study · Randomized controlled trial · 1996

1 result

A double-blind comparison of nafarelin and leuprolide acetate for down-regulation in IVF cycles.

Corson SL, Gutmann JN, Batzer FR, Gocial B

International journal of fertility and menopausal studies1 Sept 1996Cited by 2 (Europe PMC)

PMID8934250 (opens in a new tab)PepBankPUB-08934250

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In IVF patients, nafarelin and leuprolide did not differ in the measured hormonal and oocyte variables.

    In plain wordsIn IVF patients, measured hormonal and oocyte variables did not differ between nafarelin and leuprolide.

    Peptide
    Nafarelin
    Outcome
    No significant changeMeasured IVF hormonal and oocyte variables
    Study

    n: not reported in source

    Comparator
    Leuprolide acetate
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There were no differences between the two groups in the areas studied.
    2 context sentences
    Summary · context
    Variables measured included the usual hormonal values as well as oocyte data, but not pregnancy rates, because of sample size and the heterogeneity of the study group.
    Summary · context
    Patients in a private IVF program who received both nasal spray and subcutaneous injections starting in the luteal phase prior to intended stimulation with any one route containing active drug in a randomized, prospective, double-blind study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.